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Abstract
Background: Headaches are more frequent in Chronic Fatigue Syndrome (CFS) than healthy control (HC) subjects.
The 2004 International Headache Society (IHS) criteria were used to define CFS headache phenotypes.
Methods: Subjects in Cohort 1 (HC = 368; CFS = 203) completed questionnaires about many diverse symptoms by
giving nominal (yes/no) answers. Cohort 2 (HC = 21; CFS = 67) had more focused evaluations. They scored
symptom severities on 0 to 4 anchored ordinal scales, and had structured headache evaluations. All subjects had
history and physical examinations; assessments for exclusion criteria; questionnaires about CFS related symptoms
(0 to 4 scale), Multidimensional Fatigue Inventory (MFI) and Medical Outcome Survey Short Form 36 (MOS SF-36).
Results: Demographics, trends for the number of diffuse “functional” symptoms present, and severity of CFS case
designation criteria symptoms were equivalent between CFS subjects in Cohorts 1 and 2. HC had significantly
fewer symptoms, lower MFI and higher SF-36 domain scores than CFS in both cohorts. Migraine headaches were
found in 84%, and tension-type headaches in 81% of Cohort 2 CFS. This compared to 5% and 45%, respectively, in
HC. The CFS group had migraine without aura (60%; MO; CFS+MO), with aura (24%; CFS+MA), tension headaches
only (12%), or no headaches (4%). Co-morbid tension and migraine headaches were found in 67% of CFS. CFS+MA
had higher severity scores than CFS+MO for the sum of scores for poor memory, dizziness, balance, and numbness
("Neuro-construct”, p = 0.002) and perceived heart rhythm disturbances, palpitations and noncardiac chest pain
("Cardio-construct"; p = 0.045, t-tests after Bonferroni corrections). CFS+MO subjects had lower pressure-induced
pain thresholds (2.36 kg [1.95-2.78; 95% C.I.] n = 40) and a higher prevalence of fibromyalgia (47%; 1990 criteria)
compared to HC (5.23 kg [3.95-6.52] n = 20; and 0%, respectively). Sumatriptan was beneficial for 13 out of 14
newly diagnosed CFS migraine subjects.
Conclusions: CFS subjects had higher prevalences of MO and MA than HC, suggesting that mechanisms of
migraine pathogenesis such as central sensitization may contribute to CFS pathophysiology.
Clinical Trial Registration: Georgetown University IRB # 2006-481
ClinicalTrials.gov NCT00810329
Background
Headaches are common complaints in Chronic Fatigue
Syndrome (CFS) and fibromyalgia (FM) [1,2]. However,
the characteristics of these headaches are poorly defined
with regards to the International Headache Society cri-
teria (IHS) [3].
The CFS case designation requires a 6 month history
of persistent, unexplained fatigue that causes significant
impairment of activity, plus 4 of 8 associated criteria [1].
These criteria include exertional exhaustion, cognitive
and sleep disturbances, and diffuse bodily pain including
headaches. Fatigue was verified using a 5 point anchored
ordinal scale [4] and the Multidimensional Fatigue
Inventory [5]. Disability and impaired quality of life
were confirmed using the Medical Outcomes Survey
Short Form 36 (SF-36) [6]. Headache severity was
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were compared between groups using the McGill Pain
Short Form [7]. Acute and chronic medical, surgical and
p s y c h i a t r i cc o n d i t i o n sw e r er u l e do u tb yh i s t o r ya n d
physical examinations.
Headaches and other CFS related symptoms overlap
with fibromyalgia (FM) criteria. The 1990 American
College of Rheumatology (ACR) research definition of
FM required 3 months of unexplained, widespread pain
plus tenderness to manual thumb pressure at ≥ 11 of 18
traditional tender points [8]. This definition has been
replaced by the 2010 FM criteria [9] that emphasize
subjective assessments of widespread pain, fatigue, unre-
freshing sleep, and cognitive difficulties. The new cri-
teria allow considerable overlap between CFS and FM
conditions.
The most prevalent headaches in the general popula-
tion are tension - type (45%), migraine (12%), sinus
(3%), and medication overuse headaches (1 - 2%)
[3,10,11]. Tension - type (T) headaches are defined by
bilateral, pressing or nonpulsatile cephalgia of mild to
moderate intensity that may last 30 minutes to 7 days.
They are not aggravated by routine physical activity
such as walking or stair climbing.
Migraine is diagnosed by having at least 5 episodes
lasting 4 to 72 hr with at least 2 of the following criteria:
(i) unilateral location; (ii) pulsatile quality; (iii) moderate
to severe pain intensity; and (iv) aggravation by physical
activities or active avoidance of movement. Either nau-
sea ± emesis, or photophobia and phonophobia must
occur. Migraines are subdivided into migraine with aura
(MA; 20% to 30% of migraineurs) and migraine without
aura (MO) [3,12,13]. The focal sensory phenomena of
the aura involves either homonymous visual symptoms
such as flickering lights, rotating discs, photosensitivity,
and loss of vision, or unilateral somatosensory distur-
bances such as paresthesias or numbness. Symptoms
appear gradually over 5 to 20 minutes and last less than
6 0m i n u t e s .T h ea u r am u s tb ed e t e c t e da tl e a s tt w i c e .
Motor function is not affected. The headache phase of
the migraine attack usually begins within 60 minutes
after the end of the aura, but sometimes is delayed for
several hours. In some cases, pain can be completely
absent. Multiple avenues of investigation including brain
magnetic resonance imaging (MRI) techniques have
associated auras with the concentric expansion of severe
and prolonged brain cortex electrical depolarization,
neurotransmitter release, vasoconstriction and reactive
hyperemia known as cortical spreading depression [14].
Increased pain sensitivity (hyperalgesia) may occur in
both MO and MA [15] due to dysfunctional pain regu-
latory mechanisms during central sensitization [16].
Since 67% of migraine subjects meet CFS criteria [2],
we propose that mechanisms of migraine may play roles
in CFS pathophysiology. If so, CFS subjects should have
elevated rates of migraine headaches compared to control
subjects. Mechanisms that differentiate MO from MA
may also be present and permit subgroup analysis in CFS.
Methods
Two cohorts of CFS [1] and healthy control (HC) sub-
jects were recruited in sequential order (Cohort 1 then
Cohort 2) using identical advertisements in the commu-
nity (e.g. newspapers) and the tertiary medical center
(e.g. posters), and information from websites [17,18]. All
subjects gave signed informed consent to take part in
this IRB - approved study.
History and physical examinations assessed the CFS
case designation criteria. “CFS” was designated by find-
ings of significant, unexplained fatigue lasting at least
6 months plus the presence of at least 4 of 8 ancillary
criteria: (i) problems with concentration or memory;
(ii) sleep disturbances; (iii) exertional exhaustion that
typically developed 24 hr after excessive physical or
mental effort; (iv) muscle pain; (v) joint pain; (vi) head-
aches; (vii) sore throat; and (viii) sore lymph node
regions in the cervical, axillary or inguinal areas [1].
These CFS symptoms were scored in nominal fashion as
“present” or “absent”. In addition, subjects scored the
severity of each symptom in the previous 6 months
using a 5 point, anchored ordinal scale [4]. Scores were
0 for no symptom, 1 for trivial, 2 for mild, 3 for moder-
ate and 4 for severe complaints. Inclusion of “trivial”
allowed subjects to acknowledge complaints that were
present but not bothersome enough to warrant treat-
ment or other lifestyle adaptations [19]. Subjects with
untreated endocrine, major psychiatric, cardiovascular,
infectious (e.g. HIV), neoplastic, and other chronic dis-
eases that may have accounted for fatigue, body pain,
headache or other symptoms were excluded.
Cohort 1 was assessed by a series of questionnaires,
history and physical examinations. Different combina-
tions of questionnaires were used during their recruit-
ment period. Preliminary results from Cohort 1
suggested an increased prevalence of migraine in CFS
compared to HC.
Next, Cohort 2 was recruited. Subjects completed an
optimized set of questionnaires and had formalized clin-
ical interviews to diagnose migraine with (MA) and
without (MO) aura, and tension - type (T) headaches
based on IHS criteria (as outlined in the Introduction)
[3]. CFS subjects were classified as CFS+MA, CFS+MO,
and CFS+T, respectively. About two - thirds of CFS
+MA and CFS+MO subjects had co-morbid tension-
type headaches. For statistical convenience, the CFS+T
group included 3 subjects with no headaches.
The Multidimensional Fatigue Inventory was used to
verify the presence of significant physical, mental, and
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assessed by the Medical Outcomes Survey Short Form
36 (SF-36) domain scores [6]. Pain complaints were sub-
jectively assessed using the McGill Pain Short Form with
its Affective, Sensory and Total Scores [7]. Subjects
completed a multisystem complaints questionnaire that
evaluated the nominal presence or absence of migraine
and tension headaches, musculoskeletal, airway, thoracic,
bowel, bladder and other symptoms over the previous 3
months [4].
The frequencies of several symptoms from individual
systems were found to be highly correlated with each
other in preliminary studies. Therefore, questionnaires
were modified to also score the severities of each symp-
tom. The same 0 to 4 point, anchored, ordinal scale was
used, and data collected for some Cohort 1 and all Cohort
2 subjects. The severity scores for the selected symptoms
were again found to correlate with each other and the
Fatigue Severity Score. The sum of severity scores for
numbness in the arms and legs, problems with memory,
dizziness and balance was calculated and accounted for
32% of the explained variance (R
2) between these queries
and the Fatigue Score. This sum was defined as the
“Neuro-construct” (score range of 0 to 16). A “Cardio-con-
struct” was developed as the sum of scores for rapid heart
rate, irregular heart rate, palpitations, and chest pain
(range 0 to 16). The explained variance was 30%.
FM was assessed using the 1990 American College of
Rheumatology (ACR) research definition. Diagnosis of
FM required 3 months of unexplained, widespread pain
affecting all 4 quadrants of the body and the axial skele-
ton, plus tenderness to manual thumb pressure (~4 kg)
at ≥ 11 of 18 traditional tender points [8]. Pressure -
induced pain thresholds were measured by pushing a
strain gauge tipped with a 1cm
2 rubber tip (dolorimeter)
at a rate of 1 kg/sec on the same 18 anatomical sites.
The average was the systemic pain threshold (kg). The
pressure required to cause pain was also measured over
the frontal, ethmoid and maxillary paranasal sinus
regions. The average was the sinus pain threshold [20].
Means and 95% confidence intervals were calculated
for each variable in the HC and CFS groups [21,22].
Cohort 1 HC and CFS outcomes were compared using
2-tailed unpaired Student’s t-tests with Bonferroni cor-
rections for multiple comparisons (p × 138 comparitors)
to identify significant differences. Fisher’s Exact tests
evaluated differences in proportions [21]. Significance
was ascribed to p ≤ 0.05.
The Cohort 2 HC and CFS and headache subtype data
were compared by analysis of variance (ANOVA). If sig-
nificant, variables were compared by 2-tailed unpaired
Student’s t-tests with Bonferroni corrections. Fisher’s
Exact tests were used as appropriate.
Results
Demographics, Disability, and Fatigue
There were no significant differences in age or gender
distribution between HC and CFS subjects in either
Cohort 1 or Cohort 2 after Bonferroni corrections of p
values (Table 1). There were no significant differences
of age, gender, or body mass index (BMI) for Cohort 2
HC and the CFS plus headache subtypes.
Most of the CFS subjects from both cohorts had rapid
onset of CFS symptoms following an initiating event.
Twenty-three of the Cohort 2 CFS subjects reported
motor vehicle accidents, head trauma, or concussions
within 5 years of the onset of their migraines (34%).
Five felt they had severe flu-like illnesses that never
improved. Three gave histories of prolonged, high dose
exposures to volatile organic compounds, and two stated
symptoms began soon after extensive series of immuni-
zations. Three had perimenstrual migraines that pre-
dated their CFS.
The HC groups within both cohorts had significantly
better quality of life (higher scores) for all domains of
the SF-36 compared to CFS subjects (Table 2). Role
Emotional and Mental Health domains for the Cohort 2
CFS headache subgroups were not as significantly differ-
ent from HC (0.05 > p > 0.03) as for the other domains
(p ≤ 0.0003). The Multidimensional Fatigue Inventory
domains were significantly higher in CFS than HC in
both cohorts, and for the 3 CFS plus headache sub-
groups in Cohort 2 (Table 3). These results indicated
that the two cohorts of control and CFS subjects were
comparable to each other.
Headaches
Headache types were first assessed by self - report ques-
tionnaires. HC reported migraines in 12% (Cohort 1)
and 16% (Cohort 2), and tension headaches in 22% and
28%, respectively. Migraines were reported to be more
prevalent in the Cohort 2 CFS group (69%) compared to
Cohort 1 (39%). The point prevalence rates for tension -
type headaches were not significantly different between
Cohort 1 (62%) and 2 (76%) CFS groups. The combina-
tion of migraine plus tension headaches was claimed to
be present in 3% of HC and 61% of CFS in Cohort 1.
This combination was present in 11% of HC and 60% of
CFS in Cohort 2.
Cohort 2 subjects were interviewed using IHS criteria
to determine their headache type. Point prevalences in
HC (n = 21) were 16% migraine, 28% tension and 11%
with both. In contrast to questionnaires, interviews of
these HC subjects identified migraine in 5%, and tension
headaches in 45%. Interviews of 67 CFS subjects identi-
fied migraine in 84%, tension headaches in 81%, and
both types in 67%. MO was found in 60% (40/67), and
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that were intermittently associated with auras. Tension
headaches were present in 78% (31/40) of MO and 88%
(14/16) of MA. The CFS+T group (n = 11) included 3
with no headaches.
CFS subjects attributed the high prevalences of head-
aches to their impression that head pain was a usual
and often daily manifestation of the severe fatigue and
general pain syndrome they experienced. They were
often unaware of MO headaches and the potential to
use beneficial migraine treatments. Nonsteroidal anti-
inflammatory drugs were used by all subjects, raising
the possibility of medication overuse headaches as a
complicating factor in CFS.
Migraine frequency and treatment information were
obtained from 51 of the 67 CFS subjects. Headaches
occurred on a yearly to monthly basis in 27 subjects
(53%). Twenty of these had been previously diagnosed,
and 7 were treated with a triptan drug. Half of this sub-
set (10/20) had no specific headache evaluation or treat-
ment plan. Three subjects were symptomatic with
migraine during their interviews, and received new diag-
noses at that time. All 3 responded to sumatriptan.
Headaches were present for 1 to 7 days per week in
47% of the 51 CFS migraine subjects. Only 14 of these
24 had been previously diagnosed, and only 3 were pre-
scribed triptan drugs. Of the 11 with active headaches
during the interviews that led to new migraine
Table 1 Demographics for Cohorts 1 and 2 (mean [95% confidence intervals]; and number with percentage)
Cohort 1 Cohort 2
HC CFS HC CFS CFS+MO CFS+MA CFS+T
N 368 203 21 67 40 16 11
Age 41.1
[39.7-42.5]
44.6
[42.9-46.2]
42.1
[36.3-47.9]
46.1
[43.7-48.6]
45.4
[42.3-48.5]
46.5
[42.4-50.6]
48.4
[40.5-56.2]
Male 85 (23%) 244 (12%) 13 (62%) 23 (34%) 11 (28%) 6 (38%) 6 (55%)
BMI - - 27.6
[25.0-30.2]
29.3
[26.7-30.8]
29.2
[27.1-31.3]
29.4
[25.7-33.1]
29.7
[24.2-33.3]
Course of CFS Rapid onset (< 1 month) 48 (71%) 32 (81%) 14 (87%) 3 (23%)
Gradually progressive 19 (29%) 8 (19%) 2 (13%) 8 (77%)
Table 2 MOS-SF-36 Quality of Life Domains for Cohorts 1 and 2 (mean [95% confidence intervals]; probability)
Cohort 1 Cohort 2
Domain HC
n = 295
CFS *
n = 145
HC
n=1 9
CFS **
n=4 9
CFS+MO**
n=2 8
CFS+MA**
n=1 2
CFS+T **
n=9
Physical Functioning 71.6
[67.8-75.4]
47.6
[43.4-52.1]
p<1 0
-10
91.1
[82.4-99.7]
41.4
[34.6-48.2]
p<1 0
-10
43.7
[35.5-51.9]
p=1 0
-9
28.8
[15.6-41.9]
p=1 0
-8
51.7
[34.5-68.8]
p = 0.0001
Social Functioning 67.4
[63.2-71.6]
46.4
[41.8-51.0]
p=1 0
-9
87.5
[76.5-98.5]
26.9
[21.0-32.8]
p<1 0
-10
25.5
[17.9-33.0]
p<1 0
-10
23.9
[9.3-38.4]
p=1 0
-7
35.9
[26.2-45.7]
P = 0.000005
Role-Physical 60.5
[63.2-71.6]
18.5
[13.3-23.7]
p<1 0
-10
76.3
[57.8-94.9]
5.6
[0.8-10.4]
p<1 0
-10
8.0
[0.5-15.6]
p=1 0
-9
4.2
[-4.0-12.3]
p=1 0
-6
0
P = 0.000009
Role-Emotional 71.6
[62.8-80.3]
53.3
[46.2-60.5]
p = 0.008
86.0
[72.5-99.5]
57.6
[44.8-70.5]
59.3
[42.0-76.5]
p = 0.03
55.6
[28.5-82.7]
p = 0.04
55.6
[24.8-86.4]
p = 0.048
Mental Health 66.8
[63.0-70.5]
58.4
[54.9-61.9]
p = 0.006
79.2
[74.0-84.3]
62.6
[57.0-68.3]
64.9
[57.9-71.8]
p = 0.005
59.7
[45.1-74.2]
p = 0.007
59.6
[48.1-71.0]
p = 0.001
Vitality 50.1
[47.1-53.1]
25.4
[22.3-28.5]
p<1 0
-10
66.1
[56.5-75.8]
13.9
[10.5-17.2]
p<1 0
-10
14.8
[10.3-19.3]
p<1 0
-10
6.7
[2.1-11.2]
p=1 0
-10
20.6
[12.6-28.5]
p=1 0
-6
Bodily Pain 60.5
[56.5-64.6]
35.1
[31.4-38.8]
p<1 0
-10
83.8
[72.4-95.2]
34.1
[28.1-40.2]
p<1 0
-10
32.8
[25.3-40.3]
p=1 0
-9
30.6
[16.2-44.9]
p=1 0
-6
42.8
[29.5-56.0]
p = 0.0003
General Health 64.5
[56.5-64.6]
38.3
[34.3-42.3]
p<1 0
-10
76.8
[69.5-84.2]
33.0
[27.8-38.2]
p<1 0
-10
36.2
[28.3-44.1]
p=1 0
-8
28.8
[19.9-37.6]
p=1 0
-8
29.1
[20.9-37.4]
p=1 0
-8
2-tailed unpaired Student’s t-tests with Bonferroni corrections following ANOVA (p < 0.05): * vs. HC of Cohort 1 and ** vs. HC of Cohort 2.
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within 12 hours. In total, 13 out of 14 newly diagnosed
migraine subjects responded to sumatriptan. This indi-
cates that diagnosis of migraine and its treatment with
triptans was of significant benefit in CFS subjects.
Migraines were under diagnosed and under treated in
CFS subjects.
CFS Criteria
The severity scores for each of the 9 CFS criteria (range
0 to 4 for each item) were compiled to examine differ-
ences based on headache subtypes. Fatigue Severity
Scores were significantly lower in HC than each of the
CFS headache subgroups and the composite group of all
CFS subjects (p < 10
-7 by 2-tailed unpaired Student’s
t-tests with Bonferroni corrections following significant
ANOVA) (Figure 1). CFS and CFS headache subgroup
scores were significantly higher than HC (p < 0.006)
except for sore throat in CFS+MA (p = 0.02), and head-
ache (p = 0.03) and sore lymph nodes (p = 0.04) in the
CFS+T subgroup. Headache Severity Scores were signifi-
cantly higher in CFS+MO, CFS+MA and total CFS
groups compared to HC (p = 10
-8 by ANOVA; p ≤ 10
-6
for each comparison after Bonferroni comparisons).
Other questionnaires
McGill Pain Scores were significantly higher in the CFS
than HC groups of Cohorts 1 and 2 (Table 4). Both the
CFS+MO and CFS+MA subtypes had significantly higher
scores than HC in Cohort 2 (p = 0.0027 by ANOVA and
p < 0.007 by t-tests). These differences were driven by
the Sensory Subscale. “Neuro-construct” scores were
highest in CFS+MA (11.4 out of 16) (Table 4). CFS+MA
scores were significantly higher than HC (p = 10
-8), CFS
+MO (p = 0.002) and CFS+T (p = 0.00002; t-tests).
“Cardio-construct” scores were significantly higher for
CFS+MA (5.9 out of 16) than CFS+MO (p = 0.045;
t-tests) and CFS+T (p = 0.049). These results were con-
sistent with the elevated scores of Cohort 1 CFS subjects
(Table 4).
Fibromyalgia and dolorimetry
Significantly more CFS+MO (55.3%) and CFS+MA
(46.2%) subjects complained of widespread pain in all
four quadrants and their axial skeleton compared to HC
(10.0%; p = 0.0010 by Fisher’s Exact tests vs. All CFS)
(Table 5). Positive tender points (≥ 11/18) were found
more commonly in CFS (55.4%) than HC (5.6%; p =
0.00005). Based on the 1990 ACR criteria [4], fibromyal-
gia was present in 37.7% of CFS, 47.4% of CFS+MO,
28.5% of CFS+MA, and 11.1% in CFS+T, but none of
the HC subjects (p = 0.0022 by ANOVA).
The average pressure causing pain at the 18 tender
points was measured by dolorimetry. The CFS+MO sub-
group had a significantly lower pain threshold (2.36 kg)
compared to HC (5.23 kg; p = 0.00001 by Bonferroni
corrected t-test and p = 0.0006 by ANOVA) (Table 5).
Pain thresholds were not correlated with age or gender
(data not shown). Tenderness was assessed over the
facial sinus regions. CFS subjects had lower pain thresh-
olds (1.02 kg) than HC (1.91 kg; p = 0.0002, t-test), with
the CFS+MO subgroup being the most tender (0.87 kg;
p = 0.00001).
Discussion
CFS, FM and headaches were defined by personal his-
tory and physical examinations in this study rather than
by surveys as reported previously [2,23,24]. The head-
ache interview used for Cohort 2 identified the frequen-
cies of migraine subtypes and tension headache in both
Table 3 Multidimensional Fatigue Inventory Domains (mean [95% confidence intervals]; probability)
Cohort 1 Cohort 2
Domains HC
n = 300
CFS *
n = 170
HC
n=1 9
CFS **
N=4 9
CFS+MO**
n=2 8
CFS+MA**
N=1 2
CFS+T **
n=9
General Fatigue 10.4
[9.9-10.9]
16.4
[15.9-16.9]
p<1 0
-10
8.2
[6.7-9.6]
17.9
[17.2-18.6]
p<1 0
-10
18.3
[17.5-19.1]
p<1 0
-10
18.5
[17.0-20.0]
p=1 0
-10
15.9
[13.9-17.8]
p=1 0
-6
Physical Fatigue 9.4
[8.9-9.9]
14.6
[14.0-15.2]
p<1 0
-10
8.1
[5.8-10.3]
16.0
[15.1-16.9]
p<1 0
-10
16.3
[15.1-17.5]
p=1 0
-8
16.3
[14.6-17.9]
p = 0.00002
14.8
[12.2-16.5]
p = 0.002
Reduced Activity 8.4
[8.0-8.8]
12.7
[12.1-13.4]
p<1 0
-10
7.4
[5.7-9.2]
16.2
[15.2-17.1]
p<1 0
-10
16.3
[15.0-17.5]
p<1 0
-10
17.4
[15.8-19.1]
p=1 0
-8
14.3
[12.2-16.5]
p = 0.00001
Reduced Motivation 8.2
[7.6-8.7]
11.1
[10.5-11.7]
p<1 0
-10
8.2
[6.7-9.7]
11.9
[10.7-13.1]
P = 0.001
11.8
[10.1-13.4]
p = 0.005
13.0
[10.3-15.7]
p = 0.003
10.7
[8.8-12.5]
Mental Fatigue 8.8
[8.3-9.3]
13.2
[12.5-13.9]
p<1 0
-10
8.5
[6.9-10.1]
15.0
[13.8-16.1]
P=1 0
-8
14.7
[13.2-16.1]
p=1 0
-6
16.8
[14.7-18.8]
p=1 0
-6
13.3
[10.4-16.2]
p = 0.004
2-tailed unpaired Student’s t-tests with Bonferroni corrections following ANOVA (p < 0.05): * vs. HC of Cohort 1 and ** vs. HC of Cohort 2.
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comparable results for Cohorts 1 and 2. However, the
questionnaire findings were not accurate when com-
pared to the structured interviews. The interviews pro-
vided credibility to the presence of CFS+MA and CFS
+T subgroups despite their small sample sizes. The
interviews also demonstrated the higher rates of tension
headaches in HC, and migraine without aura (MO) in
CFS. CFS subjects with tension headaches (CFS+T)
tended to have less severe complaints compared to the
migraine subtypes. Inclusion of quality of life SF-36 and
fatigue (MFI) questionnaires confirmed the disability
0123
Lymph nodes
Sore throat
Headache
Arthralgia
Myalgia
Memory,
cognition
Exertional
exhaustion
Sleep
Fatigue
Severity Score
4
CFS+T CFS+MA CFS+MO CFS (all) HC
Figure 1 CFS symptom severity scores for Cohort 2. Symptom severities were scored on ordinal scales from 0 to 4. HC (red columns) had
significantly lower scores for each item (mean; 95% C.I. error bars) compared to all CFS (yellow columns) (p ≤ 0.006 after Bonferonni corrections).
HC scores were also significantly lower than all the CFS headache subtypes and items except sore throat in CFS+T (green bar). CFS+MA (blue
columns) had significantly higher scores than CFS+T for exertional exhaustion (p = 0.036) and sore lymph nodes (p = 0.017).
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the CFS groups.
These data verified the high prevalence of migraine
pathology in CFS [2]. The ratio of MO to MA was simi-
lar to that reported in other migraine groups [10,12].
We propose that mechanisms of migraine pathophysiol-
ogy may contribute to other CFS symptoms in addition
to headaches. If so, anti - migraine treatments may be
beneficial for CFS - related symptoms even in subjects
who do not have migraines. This speculation requires
prospective evaluation in clinical trials.
Correlates of MO and MA suggested that aura may be
associated with distinct phenotypic and pathological
alterations. Neuro-construct, Cardio-construct, and
McGill Pain Scores were higher in CFS+MA than CFS
+MO. These queries relied on self-reported perceptions
of dizziness and lightheadedness, peripheral numbness,
thoracic sensations, and higher numbers of pain descrip-
tors. It is not clear how these perceptions may be
related to the phenomenon of aura. Vertigo has been
associated with migraine as vertiginous migraines, but
has not been definitively investigated for a relationship
to aura [25,26]. The sensations of abnormal heart beat
and palpitations may be related to autonomic dysregula-
tion that is a common feature of CFS [27]. Chest pain
was not related to coronary artery disease or angina as
determined by history and physical examination, EKG’s,
and exercise stress tests in a portion of the subjects.
Noncardiac chest pain with perceptions of tachycardia
and palpitations may be due to esophageal spasms with
Table 4 Subjective scores that were significantly different from HC and CFS+MA (mean [95% C.I.]; probability)
Cohort 1 Cohort 2
HC CFS HC All CFS CFS+MO CFS+MA CFS+T
Headache Severity Score 0.85
[0.69-1.01]
N = 191
2.64
[2.45-2.83]
n = 152
p<1 0
-10 *
0.55
[0.11-0.99]
n=2 0
2.63
[2.33-2.93]
n=6 3
p<1 0
-9 **
2.76
[2.39-3.13]
n=3 8
p<1 0
-8 **
2.93
[2.43-3.43]
n=1 4
p=1 0
-6 **
1.82
[1.08-2.56]
n=1 1
p = 0.03 **
McGill Sensory Score 6.5
[5.2-8.8]
n = 109
8.8
[7.0-10.5]
n=5 5
p = 0.002 *
4.3
[0.9-7.7]
n=1 8
13.9
[11.5-16.3]
n=4 4
p = 0.0004**
13.6
[10.5-16.6]
n=2 4
p = 0.002**
17.5
[11.6-23.4]
n=1 2
p = 0.002 **
9.50
[7.0-12.0]
n=8
Neuro-Construct 2.39
[1.58-3.20]
n=5 7
7.00
[4.91-9.01]
n=2 1
p = 0.000005*
1.71
[0.36-3.06]
n=1 7
7.08
[5.93-8.23]
n = 48 p = 0.00003**
6.33
[4.92-7.74]
n=3 0
p = 0.0007**
p = 0.002***
11.4
[10.3-12.5]
n=1 0
p=1 0
-8 **
4.50
[2.84-6.16]
n=8
p = 0.00002***
Cardio-Construct 1.46
[0.79-2.13]
n=5 7
2.86
[1.45-4.27]
n=2 1
p = 0.053
0.76
[-0.07-1.59]
n=1 7
3.22
[2.30-4.14]
n=4 5
p = 0.02**
2.70
[1.67-3.73]
n=2 7
p = 0.045***
5.90
[3.55-8.25]
n=1 0
p = 0.0004 **
1.63
[0.65-2.61]
n=8
p = 0.049 ***
* vs. HC of Cohort 1; ** vs. HC of Cohort 2; and *** vs. CFS+MA using 2-tailed unpaired Student’s t-tests with Bonferroni corrections after ANOVA. Neuro-
Construct = sum of scores for poor memory, dizziness, balance problems, and numbness in arms or legs. Cardio-Construct = sum of scores for rapid heart rate,
irregular heart rate, palpitations, and chest pain.
Table 5 Fibromyalgia (1990 Criteria) [8] and pressure - induced pain thresholds in Cohort 2 (mean [95% confidence
intervals]; probability)
HC All CFS CFS+MO CFS+MA CFS+T
n = 20 N = 67 n = 40 n = 16 n = 10
Widespread pain 10.0% 50.0%
P = 0.0010*
55.3%
p = 0.0006*
46.2
p = 0.02*
33.3%
Manual pressure at ≥ 11/18 Points 5.6% 55.4%
p = 0.00005*
64.1%
p = 0.000013*
56.3%
p = 0.001*
20.0%
p = 0.014**
Fibromyalgia 0% 37.7%
P = 0.0004*
47.4%
P = 0.00007*
28.5%
p = 0.022*
11.1%
p = 0.03**
Systemic pain threshold (kg) 5.23
[3.95-6.52]
2.90
[2.47-3.32]
p = 0.0002
†
2.36
[1.95-2.78]
P = 0.00001
†
3.51
[2.53-4.48]
3.94
[2.67-5.20]
p = 0.025
††
Sinus pain threshold (kg) 1.91
[0.37-2.45]
p = 0.0002
† 0.87
[0.71-1.03]
p = 0.0001
†
1.18
[0.86-1.51]
1.30
[0.90-1.71]
Fisher’s Exact Test vs.* HC and vs. ** CFS+MO. 2-tailed unpaired Student’s tests with Bonferonni corrections following ANOVA (p < 0.05) vs.
† HC and vs.
†† CFS+MO.
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CFS.
Conversely, CFS+MO showed trends for an higher
prevalence of FM (1990 criteria) [8] and lower systemic
and sinus pain thresholds than CFS+MA (Table 5).
Additional testing will be required to determine if these
measures reach statistical significance when the number
of CFS+MA subjects is increased. This potential differ-
ence in tenderness (hyperalgesia) and allodynia [23]
between CFS+MA and CFS+MO was not apparent
when the severities of the pain - related symptoms such
as myalgia and arthralgia were compared (Figure 1). The
severities of neurocognitive symptoms were also equiva-
lent between CFS+MO and CFS+MA subgroups.
The current study was not designed to correlate trig-
gers of migraine or the presence of an aura with precipi-
tating factors of severe episodes of CFS complaints.
Migraine triggers include fasting, premenstrual period
hormonal status, lack of sleep, nasal irritants and odors
[30]. Similar triggers are associated with acute worsen-
ing of CFS complaints. Future studies will be needed to
identify correlates and mechanisms of aura, allodynia
and hyperalgesia development in CFS migraineurs
[16,20,23].
The association of migraine with CFS and FM intro-
duces a new perspective for “functional” somatization
disorders. We agree with Wessely et al. [31] who stated
that the existence of specific functional somatic syn-
dromes is an artifact of medical specialization and dif-
ferent systems - oriented consensus definitions of these
illnesses. This attitude is conveyed by the 2010 FM diag-
nostic criteria that overlap extensively with CFS, and
remove the importance of “tender points” [1,9].
A further stage in the evolution of CFS, FM, irritable
bowel syndrome, and other systems - based diagnoses
has been proposed by Fink and Schroder with their
hypothesis of Bodily Distress Syndrome [32]. A reevalua-
tion of the pathophysiological mechanisms contributing
to these seemingly disparate syndromes and individual
organic disorders such as migraine may lead to the
recognition of common primary pathologic, genetic and
environmental diatheses that lead to overlapping and
fluctuating patterns of organ - specific complaints.
Conclusions
CFS subjects have a high prevalence of migraine head-
aches that may be overlooked and undertreated. The
proportion with an aura was similar to other migraine
groups. CFS+MA was associated with higher severity
scores for neural problems such as numbness and dizzi-
ness, and alterations of heart beat. The lower pressure -
induced pain thresholds and hyperalgesia found in the
CFS+MO subgroup was suggestive of nociceptive hyper-
responsiveness and central sensitization. Appropriate
diagnosis and treatment with triptans may be beneficial
for CFS subjects and their complex headaches.
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